A single-centre experience of intravenous thrombolysis for stroke in COVID-19 patients

Davide Sangalli1, Valeria Polonia2,3, Daniele Colombo2

  • 1Unit of Neurology, "Alessandro Manzoni" Hospital - ASST Lecco, Via dell'Eremo 9/11, 23900, Lecco, Italy. d.sangalli@asst-lecco.it.

Insights

Intravenous thrombolysis for acute ischemic stroke in COVID-19 patients presents significant risks. This study highlights unpredictable complications and high mortality, questioning the risk-benefit balance of rt-PA in these cases.

Area of Science:

  • Neurology
  • Infectious Diseases
  • Cardiovascular Medicine

Background:

  • The Coronavirus Disease 2019 (COVID-19) pandemic created unprecedented challenges in managing acute ischemic stroke.
  • The safety and efficacy of intravenous thrombolysis, particularly recombinant tissue plasminogen activator (rt-PA), in COVID-19 positive patients remain unclear.

Observation:

  • This study details four cases of acute ischemic stroke in patients with confirmed COVID-19 who underwent intravenous thrombolysis.
  • These patients exhibited unusual stroke features and experienced severe, unexpected complications post-treatment.

Findings:

  • The administration of rt-PA in acute ischemic stroke patients with COVID-19 was associated with a very high overall mortality rate.
  • The risk-benefit profile of intravenous thrombolysis in this specific patient population appears unfavorable due to unpredictable adverse events.

Implications:

  • These findings suggest a need for cautious consideration of intravenous thrombolysis in acute ischemic stroke patients who are also positive for COVID-19.
  • Further research is warranted to understand the pathophysiology and to establish optimal management strategies for acute ischemic stroke in the context of COVID-19 infection.

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
189
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
144
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
160
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.8K
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
138
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
171